Palliative Care in Castrate-Resistant Prostate Cancer

被引:9
|
作者
Rabow, Michael W. [1 ]
Lee, Michael Xiang [2 ]
机构
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Symptom Management Serv, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
关键词
Palliative care; Castrate-resistant prostate cancer; Symptom management; QUALITY-OF-LIFE; CONTROLLED-TRIAL; MEN; HOSPICE; IMPACT; SURVIVAL; OUTCOMES; SERVICE; NEEDS; END;
D O I
10.1016/j.ucl.2012.07.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Significant symptoms and suffering related to castrate-resistant prostate cancer (CRPC) are associated with the disease and its treatment. Increasingly, with advances in treatment efficacy, men can live with symptoms for long periods. Interdisciplinary palliative care teams (including physicians, nurses, social workers, chaplains, pharmacists, psychologists, physical therapists, and nutritionists) focused on symptom management and patients' goals of care can collaborate with prostate cancer surgeons, oncologists, and radiation oncologists to provide the best care for men at all stages of treatment, including end of life. This article reviews the benefits of palliative care in helping patients with CRPC manage symptoms and distress.
引用
收藏
页码:491 / +
页数:14
相关论文
共 50 条
  • [21] Castrate-resistant prostate cancer: postdocetaxel management
    Zhao, Song
    Yu, Evan Y.
    CURRENT OPINION IN UROLOGY, 2013, 23 (03) : 201 - 207
  • [22] Pharmacotherapeutic strategies for castrate-resistant prostate cancer
    Moussa, Mohamad
    Papatsoris, Athanasios
    Abou Chakra, Mohamed
    Sryropoulou, Despoina
    Dellis, Athanasios
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (12) : 1431 - 1448
  • [23] New therapies for castrate-resistant prostate cancer
    Williams, Stephen B.
    Lay, Aaron H.
    Lau, Clayton S.
    Josephson, David Y.
    Wilson, Timothy G.
    Choueiri, Toni K.
    Pal, Sumanta K.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (13) : 2069 - 2074
  • [24] Emerging therapies in castrate-resistant prostate cancer
    Zarour L.
    Alumkal J.
    Current Urology Reports, 2010, 11 (3) : 152 - 158
  • [25] Emerging therapies in castrate-resistant prostate cancer
    Lassi, Kiran
    Dawson, Nancy A.
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (03) : 260 - 265
  • [26] Towards a new era in care for metastatic castrate-resistant prostate cancer
    Mason, Malcolm
    JOURNAL OF CLINICAL UROLOGY, 2011, 4 (01) : S1 - S1
  • [27] Current clinical trials in castrate-resistant prostate cancer
    Petrylak D.P.
    Current Urology Reports, 2011, 12 (3) : 173 - 179
  • [28] Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
    Beckett, Robert D.
    Rodeffer, Kathryn M.
    Snodgrass, Rachel
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1016 - 1024
  • [29] Future Directions in Castrate-Resistant Prostate Cancer Therapy
    Antonarakis, Emmanuel S.
    Carducci, Michael A.
    CLINICAL GENITOURINARY CANCER, 2010, 8 (01) : 37 - 46
  • [30] Treatment sequencing in metastatic castrate-resistant prostate cancer
    Sartor, Oliver
    Gillessen, Silke
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 426 - 431